Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Benitec Biopharma Inc.NASDAQ: BNTC
Short-term Investments · Q3 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q3 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Short-term Investments vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 short-term investments of $0 is the 8th highest of the 10 companies compared; the peer median is $24.83M.
- Short-term investments amounts to 0.0% of total assets for BNTC, versus a peer median of 15.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $119.02M | -46.3% | — | 45.2% | |
| Mar 2026 | $98.51M | -76.6% | — | 18.7% | |
| Mar 2026 | $91.14M | -53.3% | -19.1% | 42.7% | |
| Mar 2026 | $83.58M | -13.2% | +29.9% | 19.8% | |
| Dec 2025 | $24.83M | -71.4% | -50.1% | 4.6% | |
| Mar 2026 | $17.44M | +91700.0% | -31.4% | 15.9% | |
| Mar 2026 | $494K | -79.3% | +4.5% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $24.83M | -53.3% | -19.1% | 15.9% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.